C4 Therapeutics vs Sutro Biopharma
CCCC and STRO side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CCCC and STRO compare
C4 Therapeutics is the larger company, worth 2.1 times as much as Sutro Biopharma ($356M against $170M).
C4 Therapeutics grew revenue faster over the last twelve months (7.2% versus −56.3% for Sutro Biopharma).
C4 Therapeutics keeps more of each dollar of sales as profit, with a net margin of −282% compared with −395% at Sutro Biopharma.
C4 Therapeutics scores higher on the StockData Score (8 against 7 for Sutro Biopharma), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CCCC | STRO |
|---|---|---|
| Size and price | ||
| Market cap | $356M | $170M |
| Share price | $2.89 | $10.26 |
| Change, 1 year | 23.5% | 27.3% |
| Change, 5 years | −92.5% | −94.2% |
| Beta (5Y) | 2.52 | 2.21 |
| Employees | 104 | 137 |
| StockData Score | ||
| Total score | 8 (better) | 7 |
| Valuation score | 1 | 1 |
| Growth score | 0 | 1 (better) |
| Performance score | 2 (better) | 0 |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 11.0× | 3.7× (better) |
| P/B | 1.6× | – |
| FCF yield | −22.4% | – |
| Fair value | $2.44 | – |
| Margin of safety | −18.6% | – |
| Growth | ||
| Revenue growth (TTM) | 7.2% (better) | −56.3% |
| Revenue growth, 5Y average | – | 19.1% |
| Profitability | ||
| Operating margin | −316% (better) | −320% |
| Net margin | −282% (better) | −395% |
| FCF margin | −247% | – |
| Return on equity | −47.6% | – |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Current ratio | 5.17 (better) | 3.32 |
| Altman Z-score | −1.65 (better) | −8.74 |
| Piotroski F-score | 4 (better) | 2 |
| Dividends and buybacks | ||
| Buyback yield | 0.07% | – |
| Shareholder yield | 0.07% (better) | 0.00% |
| Ownership | ||
| Held by institutions | 95.6% | 99.4% |
| Held by insiders | 2.8% | 6.1% |
| Insider net buying, 12 months | −$22.2K | $0 (better) |
| Short interest, % of float | 38.9% | 14.5% |
Go deeper
- CCCC stock overview
- CCCC income statement
- CCCC valuation and score
- STRO stock overview
- STRO income statement
- STRO valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.